PPT-Effect of high-intensity statin therapy on

atherosclerosis in noninfarct related coronary arteries a serial intravascular ultrasonography study IBIS4 Integrated Biomarkers and Imaging Study Lorenz Räber Masanori Taniwaki Serge Zaugg. Louis H. Stein, Jessica Berger, Maryann . Tranquilli. , . John A. . Elefteriades. .. . The Aortic Institute at Yale – New Haven Hospital . Bench top to bedside interaction. . Medial Degeneration . Optimizing . patient care. William Cromwell, MD, FAHA, FNLA. Chief Medical Officer – LipoScience, Inc.. Chief – Lipoprotein and Metabolic Disorders Institute. Adjunct Associate Professor – Wake Forest University School of Medicine. James J. Lehman, DC, MBA, FACO. Associate Professor of Clinical Sciences. School of Chiropractic. Director. Community Health Clinical Education. University of Bridgeport. Learning Objectives. . Organize a clinical thought process while performing a neuromusculoskeletal evaluation of a patient with statin myopathy and piriformis syndrome.. Cardiometabolic Disease Is an Epidemic. Clinical Diagnosis of Metabolic Syndrome. Adiposity, Insulin Resistance, Inflammation and Oxidative Stress - What's the Correlation?. Typical Characteristics of the Patient With MetSyn. Beauty is in the Eye of the Beholder. Brian Asbill, MD. Asheville Cardiology Associates. Overview. NHLBI, ACC, AHA expert panel convened 2008. First new guidelines since ATP III guideline update in . Recommendations for Patient-Centered Management of Dyslipidemia Part 2: Women’s Health. Jacobson ta, et al. Journal of clinical . lipidology. Doi. : 10.1016/jacl.2015.09.002. National Lipid Association. Control. Relative risk. Absolute Effect. (per thousand). Statin. Myalgia. 348/14960. (2.3%) . 288/14520. (2.0%). 1.02. (0.88-1.19). +1. (-1 to +5). Rhabdomyolysis. 138/2454. (5.6%). 158/2446. (6.5%). of the NLA. Conclusions of the NLA Safety Task Force for Muscle Safety. Myopathy and rhabdomyolysis are associated with statin therapy, as a class effect. Elevated creatine kinase (CK) levels may indicate statin-induced muscle damage. Debra Griner, MS FNP-C. Mesa Primary Care. Casper, Wyoming. Disclosures. None. Objectives. Identify causes of hyperlipidemia (HLD). Treatment Guidelines. Who should be treated for HLD & Goal. 3. Prevention. /Lipid management in . Diabetes. Dr.Zahra. . davoudi. Endocrinology department of . Loghman. Hakim Hospital, . Shahid. . Beheshti. University of Medical Sciences. A . 65 year-old woman . with medical history of . Alfred Fisher MD PhD. Professor and Chief. Division of Geriatrics, Gerontology,. and Palliative Medicine. University of Nebraska Medical Center. Older Patients in Primary Care often take Statins. Johansen, et. al. . of. Dyslipidemia. Navid Saadat, MD. Associate Professor of Endocrinology. Shahid Beheshti University of Medical Sciences. Rationale for . Treatment. Benefit . of . LDL-C. . reduction in . CVD events. Slide deck. The full text of the paper is available at. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31652-0/fulltext. . Rationale. Lipoprotein. (a) . is. an . established. . risk. Sex . Male. Diabetes. . History. T2D, . onset. @45 . yrs. , treatment: . metformin. , . sitagliptin. and . gliclazide. . Organ. . damage. . evaluation. :. Eyes. : No . signs. of . retinopathy.